» Test Menu » Bladder Cancer Panel +3,+7,+17,9p21- by FISH Client Login | Email | Phone: 1.865.380.9746

Bladder Cancer Panel +3,+7,+17,9p21- by FISH

Test Code


Test Synonyms

+3,+7,+17, del(9)(p21)


Bladder Cancer


Fluorescence in situ Hybridization (FISH)

Turnaround Time

3-5 days

Specimen Requirements

Voided urine must be > 33 mL. Mix voided urine with preservative at 2:1 ratio of urine to preservative (PreservCyt® or Carbowax® solutions) for a total volume > 50 mL.

Specimen Stability
2°C to 8°C, specimens are stable up to 72 hours
Storage & Handling

2°C to 8°C during transit, but specimens may be transported on refrigerated gel packs. Do not allow the gel pack to come in contact with the specimen. Do not freeze. Extreme temperatures should be avoided.

Causes for Rejection

Any non-urine specimen including bladder or renal pelvic washings; Incorrect preservative; Sample exposed to extreme temperature; Insufficient volume or number of cells for analysis; Specimen transport greater than 48 hours

Reference Range

In a normal cell two orange, two green, two aqua and two gold signals will be seen. A case is considered abnormal when at least 2 of 3 signals (orange, green, or aqua) is seen in greater than or equal to 4 cells or if there is an absence of both gold signals in greater than or equal to 12 cells.


+3,+7,+17, del(9)(p21) is recommended for the evaluation of patients with hematuria who are suspected of having bladder cancer and for monitoring patients for tumor recurrence. An important advantage in the evaluation of bladder cancer patients is that the chromosome changes detected by FISH may predate the cytological changes by several months.

  1. Phillips and Richardson. (2006). Aneuploidy in bladder cancers: the utility of fluorescent in situ hybridization in clinical practice. BJU Inter.98:33-37.
  2. Sarosdy et al. (2006). Use of a multi-target fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. 176:44-47.
  3. Skacel et al. (2003). Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol. 169:2101.

PreservCyt is a trademark of Hologic, Inc.